Our Trading helps clients run and transform their front, middle and back-office trading operations. We provide buy-side, sell-side and market infrastructure firms with a full-service offering, including systems integration and technology consulting services, to assist in delivering high performance trading and settlement. These apps run on a custom built blockchain, an enormously powerful shared global infrastructure that can move
Value around and represent the ownership of property. This enables developers to create markets, store registries of debts or promises, move funds in accordance with instructions given long in the past.
These apps run on a custom built blockchain, an enormously powerful shared global infrastructure that can move value around and represent the ownership of property.
Complete Omics needed to ensure their proprietary neoantigen technology was fully protected against potential infringement. The challenge was to navigate the complex patent landscape in the biotechnology sector and prepare a robust application that would withstand rigorous examination.
We conducted an in-depth analysis of Complete Omics’ technology and its unique attributes. This included reviewing scientific data, existing patents, and potential competing technologies to identify the key elements that required protection.
We performed a comprehensive patentability search and analysis to evaluate the novelty and non-obviousness of the neo-antibody technology. This step was crucial in identifying any prior art that could affect the patentability of the invention.
After thorough preparation, we drafted and filed a detailed patent application with the United States Patent and Trademark Office (USPTO). The application, U.S. Serial No. 17/346,282, included well-defined claims that covered all critical aspects of the neo-antibody technology.
During the examination process, we worked closely with the patent examiner, addressing any queries and providing additional information as required. We also amended claims where necessary to ensure they met all patentability requirements.
Our meticulous approach resulted in the successful grant of U.S. Serial No. 17/346,282 for CompleteOmics’ neo-antibody technology. This patent not only provided robust protection for their innovation but also positioned them as a leader in the field of cancer therapeutics. The granted patent has enabled CompleteOmics to attract significant investment and form strategic partnerships, further advancing their mission to improve cancer treatment outcomes.